Continuous positive airway pressure affects mitochondrial function and exhaled PGC1-α levels in obstructive sleep...

Area of Science:

• Respiratory Medicine
• Mitochondrial Biology
• Sleep Medicine

Background:

• Obstructive sleep apnea (OSA) is linked to oxidative stress, inflammation, and mitochondrial dysfunction.
• Mitochondrial dysfunction in OSA impacts both systemic and upper airway tissues.
• Assessing mitochondrial function via biomarkers in exhaled breath condensate (EBC) is an emerging area.

Purpose of the Study:

• To evaluate mitochondrial function (Mt/N ratio) and PGC1-α protein levels in EBC and plasma of OSA patients.
• To determine the impact of continuous positive airway pressure (CPAP) treatment on these biomarkers.
• To investigate if EBC biomarkers reflect changes seen with OSA treatment.

Main Methods:

• Quantitative real-time PCR was used to measure the mitochondrial DNA/nuclear DNA (Mt/N) ratio in EBC and plasma.
• Enzyme-linked immunosorbent assay quantified PGC1-α protein levels in EBC and plasma.
• Comparison of biomarkers in 40 OSA patients and 20 controls before and after 3 months of CPAP treatment.

Main Results:

• OSA patients showed elevated Mt/N ratio and PGC1-α levels in EBC compared to controls.
• CPAP treatment normalized these elevated EBC biomarkers in OSA patients.
• No significant differences in Mt/N ratio or PGC1-α levels were found in plasma or blood of OSA patients before and after CPAP.

Conclusions:

• CPAP therapy effectively improves mitochondrial function and PGC1-α levels in the EBC of OSA patients.
• EBC biomarkers (Mt/N ratio, PGC1-α) are sensitive indicators of OSA-related mitochondrial changes.
• Plasma biomarkers did not reflect the therapeutic effects of CPAP observed in EBC.